Diversified Trust Co Purchases 1,769 Shares of Repligen Co. (NASDAQ:RGEN)

Diversified Trust Co lifted its position in shares of Repligen Co. (NASDAQ:RGEN) by 16.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,238 shares of the biotechnology company’s stock after purchasing an additional 1,769 shares during the period. Diversified Trust Co’s holdings in Repligen were worth $1,762,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Everence Capital Management Inc. bought a new position in Repligen during the 4th quarter worth $294,000. GAMMA Investing LLC increased its position in Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 90 shares during the period. Franklin Resources Inc. raised its stake in Repligen by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 332,405 shares of the biotechnology company’s stock worth $47,551,000 after purchasing an additional 26,668 shares in the last quarter. Peapack Gladstone Financial Corp bought a new stake in Repligen in the 3rd quarter valued at about $296,000. Finally, Tidal Investments LLC grew its position in shares of Repligen by 142.8% during the 3rd quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 6,558 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on RGEN shares. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Stock Performance

Shares of Repligen stock opened at $154.70 on Thursday. The company’s 50 day moving average price is $145.67 and its two-hundred day moving average price is $142.91. The firm has a market capitalization of $8.67 billion, a P/E ratio of -418.10, a P/E/G ratio of 4.64 and a beta of 0.97. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the business posted $0.23 EPS. On average, equities analysts forecast that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.